|
RAPGEF5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.76609999957833E-07 |
| Normal-vs-Stage3 |
1.62436730732907E-12 |
| Normal-vs-Stage4 |
6.59883259146454E-12 |
| Stage1-vs-Stage2 |
5.636000E-02 |
| Stage1-vs-Stage3 |
8.100100E-02 |
| Stage1-vs-Stage4 |
3.135200E-01 |
| Stage2-vs-Stage3 |
3.864800E-01 |
| Stage2-vs-Stage4 |
2.695200E-01 |
| Stage3-vs-Stage4 |
6.891000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
1.97648999999966E-05 |
| Normal-vs-Asian |
1.29190003139712E-09 |
| Caucasian-vs-AfricanAmerican |
9.433000E-01 |
| Caucasian-vs-Asian |
7.042600E-01 |
| AfricanAmerican-vs-Asian |
8.573800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
9.592800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
3.00870439673417E-14 |
| Normal-vs-Age(81-100Yrs) |
2.903900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.979800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.637020E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.401400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.113000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.772000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.073000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.445600E-02 |
| Classical-VS-Follicular |
1.63535851527286E-12 |
| Classical-VS-Other |
2.790200E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
3.84390000000012E-05 |
| Tall-VS-Other |
3.328400E-01 |
| Tall-VS-Normal |
1.31561428418081E-13 |
| Follicular-VS-Other |
1.960990E-01 |
| Follicular-VS-Normal |
1.43300005195357E-09 |
| Other-VS-Normal |
2.183700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
6.89936996423057E-12 |
| N0-vs-N1 |
2.135000E-01 |
|
|
